Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience
Summary
“Cerevel aims to be the premier neuroscience company by applying state-of-the-art technology and a differentiated approach to developing novel medicines,” said John Renger, Ph.D., chief scientific officer at Cerevel Therapeutics. Utilizing cutting-edge tools like Cyclica’s is one of the many ways we are creating a leading neuroscience drug discovery and development platform for the future.” “Leveraging Cyclica’s multi-targeted, proteome-wide approach, combined with Cerevel’s novel and relentless pursuit of advancing neuroscience, has the potential to bring medicines to patients suffering from neurological diseases faster,” said Vern De Biasi, vice president and global head of strategic partnerships at Cyclica. In addition to its pipeline of five clinical assets and seven pre-clinical programs, Cerevel is pursuing undisclosed targets for numerous neurological indications, including those with disease-modifying potential. “We are excited by the opportunity to combine our technological approach with Cerevel’s strong expertise in neuroscience to drive the development of meaningful therapeutics.” Terms of the collaboration with Cyclica are not disclosed. With a world-class team that has deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs.